Similarly, our study demonstrated that the expression of p-ERK and the production of inflammation were increased in an aggressive osteolysis model mediated by LPS, titanium, and breast cancer cells and that a potent inhibitor of the ERK treatment reduced inflammation and protected bone destruction (Seo et al., 2010; Lee et al., 2011; Back et al., 2021). Here, MAPK1 is linked to breast cancer.